Article thumbnail

Use of zoledronic acid in the treatment of Paget’s disease

By Margaret Seton and Stephen M Krane


This review examines the use of zoledronic acid in the treatment of Paget’s disease of bone. It begins with a brief discussion of the theories of pathogenesis of Paget’s disease, its clinical manifestations, and the history of bisphosphonate treatment in this disorder. Risk of oversuppression of bone by the more potent bisphosphonates and their association with avascular necrosis of the jaw are noted

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1999). A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget’s disease of bone. Paget’s Risedronate/Etidronate Study Group.
  2. (1993). Abnormalities in osteoclast precursors and marrow accessory cells in Paget’s disease.
  3. (1999). Alendronate in the treatment of Paget’s disease of bone.
  4. (1997). Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget’s disease of bone. Calcif Tissue Int,
  5. (2007). Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
  6. (1990). Atypical multinucleated cells form in long-term marrow cultures from patients with Paget’s disease.
  7. (2005). Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
  8. (2003). Bisphosphonate-induced osteopetrosis.
  9. (2002). Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res,
  10. (1995). Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in
  11. (1980). Cell cultures from bone affected by Paget’s disease. Arthritis Rheum,
  12. (1997). Clinical research update: zoledronate.
  13. (1996). Comparative study of alendronate versus etidronate for the treatment of Paget’s disease of bone.
  14. (2005). Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease.
  15. (2002). Development of bisphosphonates.
  16. (2002). Domain-specifi c mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget’s disease. Hum Mol Genet,
  17. (1999). Effect of multiple intravenous pamidronate courses in Paget’s disease of bone. Rev Rhum Engl Ed,
  18. (1982). Etidronate disodium in the treatment of Paget’s disease of bone.
  19. (2002). Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
  20. (2002). Incidence and natural history of Paget’s disease of bone in England and
  21. (2007). Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
  22. (2002). Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
  23. (2002). Is clinical expressiveness of Paget’s disease of bone decreasing?
  24. (2005). Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report.
  25. (2007). Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate.
  26. (2007). Managing metastatic bone pain: the role of bisphosphonates.
  27. (1993). Mineralisation defects with pamidronate therapy for Paget’s disease.
  28. (2007). Multicenter blinded analysis of RT-PCR detection methods for paramyxoviruses in relation to Paget’s disease of bone.
  29. (2007). Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
  30. (2007). Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair.
  31. (2005). Osteonecrosis of the jaw and bisphosphonates.
  32. (1996). Paget’s disease of bone and unvaccinated dogs.
  33. (2003). Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
  34. (1994). Pamidronate disodium and possible ocular adverse drug reactions.
  35. (1999). Paramyxoviruses and Paget’s disease: the affi rmative view.
  36. (1983). Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget’s disease of bone.
  37. (1994). Preclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound.
  38. (2003). Renal failure with the use of zoledronic acid.
  39. (1997). Renal tolerability profi le of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol,
  40. (2004). Risedronate and pamidronate treatment in the clinical management of patients with severe Paget’s disease of bone and acquired resistance to bisphosphonates. Calcif Tissue Int,
  41. (1999). Risedronate, a highly effective, short-term oral treatment for Paget’s disease: a dose-response study. Calcif Tissue Int,
  42. (2003). Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D defi ciency.
  43. (2005). Severely suppressed bone turnover: a potential complication of alendronate therapy.
  44. (1999). Single infusion of zoledronate in Paget’s disease of bone: a placebo- controlled, dose-ranging study.
  45. (2004). Ten years of alendronate treatment for osteoporosis in postmenopausal women.
  46. (2004). The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell,
  47. (1999). The epidemiology of Paget‘s disease in Britain: is the prevalence decreasing? J Bone Miner Res,
  48. (2002). The pro and con of measles virus in Paget’s disease: con. J Bone Miner Res, 17:2; author reply 2293.
  49. (2007). The safety of zoledronic acid. Expert Opin Drug Saf,
  50. (1981). Towards a viral etiology for Paget’s disease of bone.
  51. (2003). Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int,
  52. (1999). Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment.
  53. (2003). Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt.
  54. (2003). Zoledronate treatment in active Paget’s disease. Ann Rheum Dis,
  55. (2007). Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma/delta T cells.
  56. (2001). Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic Lesions of multiple myeloma: a phase III, double-blind, comparative trial.